NEW YORK (AFX) - Generic drug maker Teva Pharmaceutical Industries Ltd. said Thursday the Food and Drug Administration tentatively approved its version of Risperdal.
Generic drug maker Teva Pharmaceutical Industries Ltd. said Thursday the Food and Drug Administration tentatively approved its version of Risperdal. The drug, made by Johnson & Johnson's Janssen LP, treats schizophrenia and acute manic episodes associated with bipolar disorder.
The new system will allow FDA scientists to search and archive generic drug applications on their computers, instead of sorting through hundreds of pages of hard copy.
The Food and Drug Administration took one more step toward joining the information age Friday with the announcement of a new electronic filing system that could potentially speed up review times for generic drugs.
The Hudson Employment Index for Philadelphia rose 1.9 points in September to 89.4, but it remains more than 20 points lower than at the start of the year, Hudson Highland Group said. The Hudson index measures worker confidence in the job market. The professional staffing company attributed the gain to reduced concerns locally about job security.- Reid Kanaley
Oct. 3 (Bloomberg) -- Quest Diagnostics Inc., the largest U.S. operator of medical-testing centers, lost a contract with UnitedHealth Group Inc. that accounted for 7 percent of annual revenue. Quest shares had their second-biggest drop ever.
Oct. 3 (Bloomberg) -- Quest Diagnostics Inc., the largest U.S. operator of medical-testing centers, lost a contract with UnitedHealth Group Inc. that accounted for 7 percent of annual revenue. Quest shares fell the most in six years.
Oct. 3 (Bloomberg) -- Quest Diagnostics Inc., the largest U.S. operator of medical testing centers, lost a contract from UnitedHealth Group Inc. representing 7% of annual revenue.
Oct. 3 (Bloomberg) -- Quest Diagnostics Inc., the largest U.S. operator of medical testing centers, lost a contract representing 7 percent of its revenue as UnitedHealth Group Inc. awarded the business to Laboratory Corp. of America, Quest's chief rival.
NEW YORK (AFX) - Iceland-based generic drug maker Actavis Group HF still plans to snag the title of the world's third largest maker of generic drugs. But without the acquisition of Pliva ( Nachrichten ) d.d., the company will need to wait a little longer, and accomplish it with smaller acquisitions.